NCT04681430View on ClinicalTrials.gov

Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions
Corona Virus InfectionSARS-CoV-2 InfectionSARS-CoV-2 PCR Test PositiveSARS-CoV-2 Acute Respiratory Disease
Interventions
BIOLOGICAL

Convalescent plasma

transfusion of convalescent plasma (CP) with neutralizing antibodies against anti-SARS-CoV-2 ((titer of at least 1:160)

DRUG

Camostat Mesilate

Tablets over 7 days, daily dose of 600 mg split into 3 doses

DRUG

Placebo for Camostat Mesilate

Placebo Tablets over 7 days, split into 3 doses

OTHER

Standard of Care (SoC)

Control Arm for convalescent plasma (CP)

Trial Locations (6)

40225

Universitätsklinikum Düsseldorf Klinik für Hepatologie und Infektiologie, Düsseldorf

44137

Klinikum Dortmund, Dortmund

45147

Universitätsklinikum Essen, Essen

60590

Universitätsklinikum Frankfurt Medizinische Klinik 2: Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie/HIV, Frankfurt am Main

79106

Abteilung Infektiologie Klinik für Innere Medizin II Department Innere Medizin Universitätsklinikum Freiburg, Freiburg im Breisgau

81675

Klinik und Poliklinik für Innere Medizin II Klinikum rechts der Isar Technische Universität München, München

All Listed Sponsors
collaborator

The Federal Ministry of Health, Germany (Bundesministerium für Gesundheit, BMG)

UNKNOWN

lead

Heinrich-Heine University, Duesseldorf

OTHER

NCT04681430 - Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals | Biotech Hunter | Biotech Hunter